ライフサイエンスコーパス: intermediate-risk group

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 s in the high-risk group versus those in the intermediate-risk group.

2 a significant survival advantage only in the intermediate-risk group.

3 n survival was greater in the favorable- and intermediate-risk groups.

4 ts in the general community, particularly in intermediate-risk groups.

5 ty of the CHD events occur in the "low" and "intermediate" risk groups.

6 the low-risk group (0 factors), 30.9% in the intermediate-risk group (1 factor), and 41.9% in the hig

7 Specifically, 80% of the patients in the intermediate-risk group (1992 AJCC T2b, or biopsy Gleaso

8 sk group (46% of all patients analyzed), the intermediate-risk group (41%), and the high-risk group (

9 up (low-risk) (21-50 years), 103 were in the intermediate-risk group (51-70 years), and 28 were in th

10 L) and normal karyotype are classified in an intermediate-risk group, albeit this subset is heterogen

11 were in the low risk group, 68% were in the intermediate risk group and 6% were in the high risk gro

12 refine cardiovascular risk assessment in the intermediate-risk group and identify candidates for aggr

13 n cardiovascular death or MI in the low- and intermediate-risk groups and an 11.1% absolute risk redu

14 f patients with DLBCL belong to the low- and intermediate-risk groups and have a CNS relapse risk < 5

15 highest risk group, 47 and 61 months for the intermediate risk groups, and the median was not reached

16 A' (lowest) risk group, score 2 to 3 as 'B' (intermediate) risk group, and score 4 to 5 as 'C' (high)

17 the good-risk group, 22 of 211 (10%) in the intermediate-risk group, and 27 of 95 (28%) in the poor-

18 relapse, compared with 24 of 98 (24%) in the intermediate-risk group, and 37 of 82 (45%) in the poor-

19 % (94% at 0 months, 99% at 24 months) in the intermediate-risk group, and by 22% (71% at 0 months to

20 RR is higher at younger ages, in intermediate-risk groups, and when a questionnaire is us

21 For low- and intermediate-risk groups, average RDR recurrence detecti

22 on reduced RR, it did not improve OS for the intermediate-risk group but was probably of benefit in h

23 ion (by biomarkers or imaging) constitute an intermediate-risk group for whom there is controversy on

24 groups have suggested CAC screening only in intermediate-risk groups (FRS, 10% to 20%).

25 he GEP 70-gene low-risk group to identify an intermediate-risk group in multiple myeloma (MM).

26 o of bacteremia for the high-risk versus the intermediate-risk group is 4.4 (95% confidence interval,

27 group (n=76), 16.6 months (14.9-17.9) in the intermediate risk group (n=529), and 5.4 months (4.7-6.8

28 ates of 6.0% (high-risk group, n=40), 44.9% (intermediate-risk group, n=36), and 84.4% (low-risk grou

29 comparison with 5 years of TAM in a low- to intermediate-risk group of postmenopausal patients.

30 achieved less commonly in the CVD high- and intermediate-risk groups than in the low-risk group.

31 In the intermediate-risk group, the estimated disease-free surv

32 Among patients in the two intermediate-risk groups, those treated with tamoxifen o

33 the HR for mortality of the patients in the intermediate-risk group versus those in the favorable-ri

34 Median survival time in the intermediate-risk group was 14 months.

35 ore than 2 (high-risk; > 1 RF) compared with intermediate-risk group was 6.9 (3.8, 12.4).

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。